Oakdale, MN, June 09, 2021 – Salspera announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.
Attendees at BIO Digital will be able to view Salspera’s Company Presentation before live meetings in the BIO One-on-One Partnering™ system begin on June 14. To meet with us at BIO Digital, you can find registration information here.
Salspera is a private, clinical stage biotech company developing its platform of orally administered microbiome immunotherapies in solid tumors. The deep pipeline consists of orally administered microbiome immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. The lead asset, Saltikva, is currently in an on-going phase 2 clinical study in Stage 4 metastatic pancreatic cancer patients in Canada. It is also being developed in additional solid tumors with the plan to initiate further phase 2 studies. The platform consists of numerous constructs engineered to deliver among others, PD-L1, CTLA-4, IL-15 intra-tumorally. These are currently undergoing IND enabling studies with plans to move them to the clinic.
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
VP of Business Development